Niki BioSolutions, Inc. income statement NIKI
It recorded a net loss of $1.4 million. Diluted earnings per share were -$0.19.
USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.
| Line |
FY 2025
Dec 31, 2025
|
FY 2024
Dec 31, 2024
|
FY 2023
Dec 31, 2023
|
FY 2022
Dec 31, 2022
|
FY 2021
Dec 31, 2021
|
FY 2020
Dec 31, 2020
|
FY 2019
Dec 31, 2019
|
FY 2018
Dec 31, 2018
|
|---|---|---|---|---|---|---|---|---|
| Revenue |
—
|
—
|
0
|
—
|
—
|
—
|
—
|
—
|
| Cost of revenue |
—
|
—
|
0
|
—
|
—
|
—
|
—
|
—
|
| Gross profit |
—
|
—
|
0
|
—
|
—
|
—
|
—
|
—
|
| Research and development |
0
-83.9%
|
2
-57.8%
|
5
-43.6%
|
9
-15.2%
|
11
-6.2%
|
12
+67.0%
|
7
+123.7%
|
3
|
| Selling, general and administrative |
1
-14.4%
|
1
-65.3%
|
2
-63.0%
|
5
-3.5%
|
5
+11.5%
|
5
-34.2%
|
7
+49.9%
|
5
|
| Other operating income (expense) |
0
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
| Pretax income |
-1
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
| Net income |
-1
+68.1%
|
-4
-51.1%
|
-3
+71.2%
|
-10
+60.9%
|
-25
-609.1%
|
5
+124.5%
|
-20
-35.6%
|
-15
|
| Basic EPS |
-0.19
+75.6%
|
-0.78
-25.8%
|
-0.62
+77.5%
|
-2.75
+61.5%
|
-7.15
|
—
|
—
|
—
|
| Diluted EPS |
-0.19
+75.6%
|
-0.78
-25.8%
|
-0.62
+77.5%
|
-2.75
+61.5%
|
-7.15
-457.5%
|
2.00
|
—
|
—
|
| Weighted average shares, basic |
7
+34.8%
|
5
+20.6%
|
5
+26.7%
|
4
+1.9%
|
4
+12.5%
|
3
|
—
|
—
|
| Weighted average shares, diluted |
7
+34.8%
|
5
+20.6%
|
5
+26.7%
|
4
+1.9%
|
4
+11.1%
|
3
|
—
|
—
|
| Other measures | ||||||||
| Depreciation and amortization |
0
|
—
|
1
-6.8%
|
1
+1.3%
|
1
-10.6%
|
1
+2.7%
|
1
+90.5%
|
1
|
| Margins | ||||||||
| Gross margin |
—
|
—
|
2.45%
|
—
|
—
|
—
|
—
|
—
|
| Profit margin |
—
|
—
|
-654.80%
|
—
|
—
|
—
|
—
|
—
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. More on our methodology.
New to this? Read How to Read an Income Statement, With a Real Example.
Company profile
- Industry
- Measuring & Controlling Devices, NEC (SIC 3829)
- Listed as
- NIKI (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Cayman Islands
- Headquarters
- Princeton, NJ
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1734005
- Former names
- Aptorum Group Ltd (until Jun 22, 2026)
Other Measuring & Controlling Devices, NEC companies
- Thermo Fisher Scientific Inc. TMO
- Rockwell Automation, Inc ROK
- Trimble Inc. TRMB
- Onto Innovation Inc. ONTO
- Mirion Technologies, Inc. MIR
- Quantum-Si Inc QSI
- Owlet, Inc. OWLT
- Geospace Technologies Corp GEOS
Source: SEC EDGAR filings. This is company-reported data, not investment advice.